PTE
PolarityTE Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
Market Cap: 1.79 Million
Primary Exchange: NASDAQ
Website: polarityte.com
Shares Outstanding: 7.38 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.15751037891283234
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 630 trading days
From: 2018-09-20 To: 2023-06-15
Lowest Point:
PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
via: PR Newswire at 2019-06-10 04:00:00:000
SALT LAKE CITY , June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE product for har… read more...
PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
via: PR Newswire at 2019-06-10 04:00:00:000
SALT LAKE CITY , June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE product for har… read more...
PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
via: PR Newswire at 2019-06-10 04:00:00:000
SALT LAKE CITY , June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE product for har… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2016-01-19 | 2016-01-15 | 2016-01-14 | 2016-01-06 | 0.335502 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|